Jan 23, 2026
What are the eligibility criteria, risks, and long‑term outcomes for patients receiving TIL therapy (Amtagvi) for melanoma?
is an autologous tumor‑infiltrating lymphocyte (TIL) therapy for adults with that has progressed after and, for BRAF V600–positive tumors, after BRAF ± MEK inhibitors . The treatment is complex and in...